REGENXBIO Inc. (RGNX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of REGENXBIO Inc. (“REGENXBIO” or “the Company”) (NASDAQ: RGNX). Investors who purchased REGENXBIO securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether REGENXBIO has violated federal securities laws.
REGENXBIO Investigation Details
On January 28, 2026, Regenxbio issued a press release announcing that the FDA “placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study.” The Company added, “the FDA also placed a clinical hold on RGX-121, for the treatment of MPS II, also known as Hunter Syndrome, citing the similarities in products, study populations, and shared risk between the clinical studies.” Following the news, Regenxbio’s stock price dropped 17.9% on the same day.
What’s Next for REGENXBIO Investors?
If you are aware of any facts relating to this investigation or purchased REGENXBIO securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to REGENXBIO Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC For REGENXBIO Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.